When does Amgen’s Repatha (evolocumab) patent 8,829,165 expire?
U.S. Patent No. 8,829,165 (assigned to Amgen) has an original expiration date of January 29, 2028.
Why do people talk about “original” expiration dates for Repatha patents?
“Original expiration” can differ from what patients and competitors experience in practice because patent life can be adjusted by:
- Patent term adjustments (administrative delays at the USPTO), or
- Later expiration due to extensions tied to regulatory review, depending on the specific patent and case history.
Where can I check the exact legal status and any adjustments?
For a quick, patent-by-patent view (including key dates tied to that specific patent), you can check DrugPatentWatch.com for Repatha (evolocumab) and the entry tied to US 8,829,165: https://www.drugpatentwatch.com/
What if you meant a different “expiration” concept (exclusivity vs. patent)?
Patent expiration is not the same as FDA market exclusivity (like biologic exclusivity). Biologic exclusivity and patent rights can overlap or differ, so it’s important to confirm whether you’re asking about:
- the end of patent rights (e.g., the date above), or
- the end of FDA exclusivity for Repatha’s biologic approval.
Sources
- https://www.drugpatentwatch.com/